The United Laboratories International Holdings Limited Stock price

Equities

3933

KYG8813K1085

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
8.96 HKD -3.03% Intraday chart for The United Laboratories International Holdings Limited -6.08% +27.82%
Sales 2023 14.89B 1.9B Sales 2024 * 15.62B 2B Capitalization 16.79B 2.15B
Net income 2023 2.93B 374M Net income 2024 * 2.57B 329M EV / Sales 2023 0.86 x
Net cash position 2023 * 5.04B 644M Net cash position 2024 * 9.3B 1.19B EV / Sales 2024 * 0.48 x
P/E ratio 2023
4.35 x
P/E ratio 2024 *
6.52 x
Employees 15,000
Yield 2023 *
2.67%
Yield 2024 *
2.85%
Free-Float 53.17%
More Fundamentals * Assessed data
Dynamic Chart
The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
The United Laboratories International's 2023 Profit Rises on Higher Revenue MT
The United Laboratories International Forecasts Profit Surge in 2023 MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
United Laboratories Postpones EGM Due to Bad Weather MT
United Laboratories Subsidiary Gets US FDA Nod for Injectable for Diabetes; Shares Rise 8% MT
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection CI
The United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023 CI
United Laboratories Controlling Shareholder to Sell 64 Million Shares MT
United Laboratories International Unit Gets Regulatory Nod to Conduct Trial on TUL01101 Tablets MT
Chinese Regulator Allows Clinical Trial of United Laboratories' Fatty-Liver Drug MT
The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection CI
United Laboratories International Says Two Products Pass Consistency Evaluation MT
China Greenlights United Laboratories' Clinical Trial for Obesity Injection; Shares Rise 4% MT
The United Laboratories International Holdings Limited Announces Approval for Clinical Trial of Ubt251 Injection on Indication of Overweight or Obesity CI
More news
1 day-3.03%
1 week-6.08%
Current month+5.41%
1 month+7.43%
3 months+30.61%
6 months+12.70%
Current year+27.82%
More quotes
1 week
8.64
Extreme 8.64
10.06
1 month
8.18
Extreme 8.18
10.06
Current year
6.56
Extreme 6.56
10.06
1 year
5.42
Extreme 5.42
10.06
3 years
3.17
Extreme 3.17
10.06
5 years
3.17
Extreme 3.17
10.06
10 years
2.70
Extreme 2.7
10.06
More quotes
Managers TitleAgeSince
Chairman 46 10-04-02
Director of Finance/CFO 62 -
Director/Board Member 61 10-10-31
Members of the board TitleAgeSince
Director/Board Member 62 07-05-24
Director/Board Member 52 07-05-24
Director of Finance/CFO 62 -
More insiders
Date Price Change Volume
24-03-28 8.96 -3.03% 10 744 511
24-03-27 9.24 -4.84% 6,118,500
24-03-26 9.71 +0.83% 3,499,507
24-03-25 9.63 -0.82% 2,174,000
24-03-22 9.71 +1.78% 4,712,000

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.24 HKD
Average target price
11.39 HKD
Spread / Average Target
+23.27%
Consensus
  1. Stock
  2. Equities
  3. Stock The United Laboratories International Holdings Limited - Hong Kong S.E.